Belgium
Ablynx, a Sanofi company headquartered in Belgium, is innovating in the biotechnology sector with its development of Nanobodies®. These proprietary therapeutic proteins merge the benefits of conventional antibodies with characteristics of small-molecule drugs to combat life-threatening diseases.
The company's focus on areas such as inflammation, hematology, immuno-oncology, and oncology underscores its potential in addressing major health challenges. Since being founded in 2001, Ablynx has carved a niche in the discovery and advancement of Nanobody-based therapies.
The €3.90B acquisition by Sanofi in June 2018 highlights the pharmaceutical giant’s dedication to pioneering innovation through Ablynx’s unique technology, aiming to develop treatments that can target multiple diseases with single, multi-specific molecules. Through this strategic investment, Sanofi is bolstering its commitment to rapid advancement of these therapeutic programs, enhancing their potential impact on the industry.
